NCOA5: A Potential Drug Target and Biomarker for Various Diseases

Target Name: NCOA5

NCBI ID: G57727

NCOA5

NCOA5: A Potential Drug Target and Biomarker for Various Diseases

The nuclear receptor coactivator 5 (NCOA5) is a protein that plays a crucial role in nuclear receptor signaling. It is a key coactivator of the transcription factor nuclear receptor activating receptor B (BRRB), which is responsible for regulating various physiological processes in the body. NCOA5 has been identified as a potential drug target and biomarker for various diseases, including cancer, obesity, and neurodegenerative disorders.

The discovery of NCOA5

NCOA5 was first identified in the late 1990s as a coactivator of the BRRB. The BRRB is a protein that plays a central role in regulating gene expression by binding to specific DNA sequences. NCOA5 is a 22-kDa protein that contains a N-terminal alpha -helix, a central beta-sheet, and a C-terminal T-loop. It is composed of two distinct domains: an N-terminal alpha-helix domain and a C-terminal T-loop domain.

The N-terminal alpha-helix is 鈥嬧?媡he primary structural domain of NCOA5 and is responsible for the protein's stability and interaction with other proteins. The alpha-helix is 鈥嬧?媋 loop of amino acids that is composed of five amino acids: Asp-22, Asp -23, Asp-24, Asp-25, and Asp-26. The alpha-helix is 鈥嬧?媐ormed by a specific sequence of amino acids, which includes Asp-22 and Asp-23, and is critical for the protein's stability.

The C-terminal T-loop domain is the second structural domain of NCOA5 and is responsible for the protein's interaction with the BRRB. The T-loop is a loop of amino acids that is composed of four amino acids: Asp-27, Asp- 28, Asp-29, and Asp-30. The T-loop is important for the protein's interaction with the BRRB because it is able to form a stable complex with the BRRB.

The NCOA5 gene

The NCOA5 gene is located on chromosome 18 at position 6.1 kb. It is a member of the evolutionarily conserved superfamily of N-coiled proteins, which includes proteins that play a central role in various cellular processes, including cell signaling, gene regulation, and DNA replication.

The NCOA5 gene is expressed in many different tissues and cells in the body, including the brain, heart, muscle, and gastrointestinal tract. It is also expressed in various cell types, including neurons, macrophages, and cancer cells.

The role of NCOA5 in nuclear receptor signaling

NCOA5 is a key coactivator of the BRRB, which is a protein that plays a central role in regulating gene expression by binding to specific DNA sequences. The BRRB is composed of four subunits, which are responsible for different aspects of gene regulation.

The N-terminal alpha-helix domain of NCOA5 is critical for the protein's interaction with the BRRB. The alpha-helix is 鈥嬧?媐ormed by a specific sequence of amino acids, which includes Asp-22 and Asp-23. The alpha-helix is 鈥嬧?媔mportant for the protein's stability and interaction with the BRRB because it is able to form a stable complex with the BRRB.

The C-terminal T-loop domain of NCOA5 is also important for the protein's interaction with the BRRB. The T-loop is a loop of amino acids that is composed of four amino acids: Asp-27, Asp-28, Asp-29 , and Asp-30. The T-loop is able to form a stable

Protein Name: Nuclear Receptor Coactivator 5

Functions: Nuclear receptor coregulator that can have both coactivator and corepressor functions. Interacts with nuclear receptors for steroids (ESR1 and ESR2) independently of the steroid binding domain (AF-2) of the ESR receptors, and with the orphan nuclear receptor NR1D2. Involved in the coactivation of nuclear steroid receptors (ER) as well as the corepression of MYC in response to 17-beta-estradiol (E2)

The "NCOA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCOA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets